Atrial fibrillation is an established prothrombotic disease that may lead to ischaemic stroke. The FVL mutation is known to be a risk for venous thromboembolism and is also connected with arterial disease and unfavourable outcomes of pregnancies in carriers. The aim of this sub-analysis, presented by PhD student Erin Mathiesen Hald (UiT The Arctic University of Norway, Norway), was to evaluate a possible association of FVL with atrial fibrillation and successive ischaemic stroke.
This analysis included data form a randomly selected sub-cohort of 3,663 subjects from the fourth survey of general population within the Tromsø Study (1994/1995). Blood samples from all participants were analysed for FVL genotype, and cases of atrial fibrillation and ischaemic stroke were determined until 31 December 2012. The risks for atrial fibrillation and ischaemic stroke in patients with FVL mutation were evaluated by calculation of hazard ratios (HR) using Cox proportional hazard regression models.
Among the study subjects, 545 had a diagnosis of atrial fibrillation and 314 suffered an ischaemic stroke. Of the participants, 235 (6.4%) were carriers of ≥ 1 risk allele in FVL. The regression identified an overall 1.4-fold higher risk of atrial fibrillation for study participants who carried an FVL mutation. Interestingly, only men but not women with FVL mutation had a 50% elevated relative risk for atrial fibrillation. Yet, their risk for ischaemic stroke was not significantly raised. Although the hazard of sustaining a stroke was enhanced in people who developed atrial fibrillation (HR 3.22), FVL mutation did not contribute to this risk.
Posted on
Previous Article
« Increased rates of arterial thromboembolism in cancer patients Next Article
Guidelines adherence reduces bleeding risk after surgery and childbirth for VWD patients »
« Increased rates of arterial thromboembolism in cancer patients Next Article
Guidelines adherence reduces bleeding risk after surgery and childbirth for VWD patients »
Table of Contents: ISTH 2020
Featured articles
Haemophilia and Rare Bleeding Disorders
Novel gene therapy leads to normal FIX activity levels in severe haemophilia B
Haemophilia gene therapy: progress and obstacles
Recombinant factor VIII safe and effective in PUPs A-LONG study
What’s New in Anticoagulation
Finding the sweet spot of anticoagulation in AF patients with ACS
Lower embryopathy risk with DOAC versus VKA during pregnancy
Higher thrombotic risk in NSCLC patient with ALK rearrangement
COVID-19 and Thrombosis
Crosstalk between inflammation and coagulation in severe COVID-19 infections
COVID-19 associated with higher VTE rates relative to influenza
Therapeutic anticoagulation not associated with lower mortality rates in COVID-19 ICU patients
COVID-19 not associated with heightened VTE risk after discharge
What’s New in Venous Thromboembolism
Residual pulmonary obstruction may predict risk of VTE recurrence
Less diagnostic delay in CTEPH diagnosis with novel algorithm
Risk of checkpoint inhibitor-associated thromboembolic events important for cancer prognosis
Pearls of the Posters
Surgical bleeding risk most important determinant of bleeding outcomes
Similar bleeding rates in patients with VTE and AF treated with DOACs
Physical rehabilitation improves health outcomes after pulmonary embolism
Guidelines adherence reduces bleeding risk after surgery and childbirth for VWD patients
Factor V Leiden mutation linked to atrial fibrillation
Increased rates of arterial thromboembolism in cancer patients
Related Articles
September 7, 2020
ISTH 2020 Highlights Podcast
September 8, 2020
Surgical bleeding risk most important determinant of bleeding outcomes
September 8, 2020
Less diagnostic delay in CTEPH diagnosis with novel algorithm
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com